...
机译:HER2阳性乳腺癌表观生物学的最新进展:易感性和治疗策略
Centre for Human Genetics and Molecular Medicine School of Health Sciences Central University of;
Centre for Human Genetics and Molecular Medicine School of Health Sciences Central University of;
Centre for Human Genetics and Molecular Medicine School of Health Sciences Central University of;
Centre for Human Genetics and Molecular Medicine School of Health Sciences Central University of;
Centre for Pharmaceutical Sciences and Natural Products School of Basic and Applied Sciences;
Centre for Human Genetics and Molecular Medicine School of Health Sciences Central University of;
HER2positive breast cancer; DNA methylation; Histone modifications; ncRNA; miRNA; Susceptibility; Therapy;
机译:HER2阳性乳腺癌表观生物学的最新进展:易感性和治疗策略
机译:CDK4 / 6抑制剂:重点是响应的生物标志物和激素受体阳性HER2阴性乳腺癌的治疗后治疗策略
机译:Her2阳性乳腺癌:当前和新的治疗策略
机译:HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关:回顾性和多中心研究
机译:通过饮食和药理学干预靶向Her2阳性乳腺癌的代谢,以提高治疗效果
机译:激素受体阳性治疗的治疗策略人体表皮生长因子受体2阳性(HR + / HER2 +)乳腺癌:对目前文献的综述
机译:曲妥珠单抗耐药机制及HER2阳性乳腺癌的新治疗策略
机译:将遗传/表观遗传机制转化为乳腺癌治疗的化学策略。